Case Series
 
Low-grade serous carcinoma of the ovary: A case series and literature review
Joel Alcid1, Mark S. Shahin2
1Resident, Internal Medicine, Drexel, Philadelphia, PA, USA
2Attending, Gynecologic Oncology, Abington-Jefferson Health Hanjani Institute for Gynecologic Oncology, Abington, PA, USA

Article ID: 100052Z10JA2018
doi: 10.5348/100052Z10JA2018CS

Corresponding Author:
Joel Alcid,
Hahnemann University Hospital / Drexel Medicine,
239 N Broad St, Philadelphia PA,
USA, 19102

Access full text article on other devices

  Access PDF of article on other devices

[HTML Full Text]   [PDF Full Text] [Print This Article]
[Similar articles in PubMed] [Similar articles in Google Scholar]



How to cite this article
Alcid J, Shahin MS. Low-grade serous carcinoma of the ovary: A case series and literature review. J Case Rep Images Oncology 2018;4:100052Z10JA2018.


ABSTRACT

Introduction: Low-grade serous ovarian cancer is a rare subtype of epithelial ovarian cancer that is generally resistant to cytotoxic chemotherapy. We present a case series of patients diagnosed with low-grade serous ovarian carcinoma and review of the literature. Serous carcinoma represents the most common histologic subtype of epithelial ovarian cancer. Low-grade serous carcinoma of the ovary may occur de novo or following a diagnosis of serous tumor of low malignant potential. The primary modality of treatment for these patients is surgery. For patients with stage II-IV low-grade serous carcinoma, the standard is maximum cytoreductive surgery, with the goal of achieving minimal residual disease, followed by chemotherapy. Although low-grade serous carcinoma of the ovary carries a relatively good prognosis, over 80% of patients will experience disease recurrence.

Case Series: We report four cases of patients ages 31-58, with a diagnosis of low-grade serous ovarian cancer. Our patients were treated with cytoreductive surgery, chemotherapy and hormonal therapy. Two of our patients were also enrolled in a MEK inhibitor clinical trial. We describe in detail the clinical course of each patient and provide a review of low-grade serous ovarian cancer.

Conclusion: Low-grade serous ovarian cancer is a rare subtype of epithelial ovarian cancer with a relatively good prognosis and high rate of disease recurrence. Due to the expression of estrogen receptors on these tumors, hormonal treatment has been shown to decrease the risk of recurrence compared with surveillance. Targeted therapy for recurrent disease has also been shown to have promising results.

Keywords: Chemotherapy, Hormonal therapy, Low-grade serous carcinoma, Ovarian cancer


[HTML Full Text]   [PDF Full Text]

Author Contributions
Joel Alcid – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of version to be published
Mark S. Shahin – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of version to be published
Guarantor of Submission
The corresponding author is the guarantor of submission.
Source of Support
None
Consent Statement
Written informed consent was obtained from the patient for publication of this case series.
Conflict of Interest
Author declares no conflict of interest.
Copyright
© 2018 Joel Alcid et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.